Loading clinical trials...

Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer | Clinical Trials | Clareo Health

COMPLETED

Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer

Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer at Moffitt Cancer Center and Lehigh Valley Hospital

NCT01662609•H. Lee Moffitt Cancer Center and Research Institute

View on ClinicalTrials.gov

Summary

The purpose of this study is to find out whether Endoscopic Ultrasound (EUS) can detect early stage pre-cancerous or cancerous changes in the pancreas in patients at high-risk for the development of pancreatic cancer. Endoscopic refers to the use of an instrument called an endoscope - a thin, flexible tube with a tiny video camera and light on the end. Ultrasound refers to an imaging technique that uses sound waves to produce pictures. EUS in this research study is a method of combining endoscopy and ultrasound imaging to obtain high quality images of the pancreas.

Eligibility

Age

30 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•* If only 2 family members are affected then both must have had pancreatic cancer and a first-degree relationship with individual screened
•* If there are more than 2 affected individuals on the same side of the family at least one of the individuals must have a first-degree relationship with the member being screened
•* Patients at least 40 years old or 10 years younger than the youngest affected individual
•Peutz-Jeghers Syndrome (PJS) patients age\>30
•Hereditary pancreatitis patients
•Patients with Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM)
•Patients with BRCA2 mutation and at least one first or second degree relative with documented pancreatic cancer
•Willingness to undergo (EUS) with possible Fine Needle Aspiration (FNA)
•Willingness to undergo surgical evaluation for abnormal EUS/FNA finding
•Willingness to undergo radiographic evaluation if screening findings are abnormal

Exclusion Criteria

•Medical contraindications to undergoing endoscopy or obstruction of the GI tract that precludes passage of the endoscope
•Personal history of pancreatic adenocarcinoma
•Previous partial or complete resection of the pancreas for adenocarcinoma
•Prior partial or total gastrectomy with Billroth II or Roux-en-Y anastamosis
•Previous computed tomography (CT) scan, magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP) or EUS of the abdomen in the past 3 years
•Coexisting cancer in other organs or acquired immunodeficiency syndrome/human immunodeficiency virus (AIDS/HIV)
•Life expectancy less than 5 years
•Pregnancy

Locations (2)

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States

Lehigh Valley Health Network

Allentown, Pennsylvania, United States

Key Dates

Start Date

August 23, 2007

Primary Completion Date

August 16, 2022

Completion Date

August 16, 2022

Last Updated

October 7, 2022

Enrollment

ACTUAL participants

Conditions

Pancreatic Cancer

Interventions

Endoscopic Ultrasound (EUS)

PROCEDURE

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 7, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer

Inclusion Criteria

Exclusion Criteria

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Resilience and Equity in Aging, Cancer, and Health (REACH)

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients